Back to News & Events

CFB Announces New Bioentrepreneur & Executive-In-Residence

March 5, 2020

The Center for Biotechnology at Stony Brook University has announced the appointment of Dr. Mario R. Mendoza as Executive-In-Residence, and Dr. William Mann as its newest BioEntrepreneur-In-Residence (BEIR). Drs. Mendoza and Mann have extensive bioscience industry experience affording them unique perspectives in their respective roles in residence at the Center for Biotechnology (CFB). Each will work with the CFB and the Long Island Bioscience Hub (LIBH), a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health. Dr. Mann will identify commercially promising academic technologies that have the potential to support company formation while Dr. Mendoza will serve in an advisory capacity for bioscience startup companies in the hub.

Dr. Mario R Mendoza is a clinical anesthesiologist (practiced at the NIH) and currently a healthcare and pharmaceutical industry medical/medical affairs consultant with over 13 years of combined experience in patient clinical care, clinical development, R&D, medical affairs (Abbott, Pfizer and Centrexion Therapeutics), and FDA medical devices regulation. Dr. Mendoza earned his BS degree in chemistry from SUNY College at Old Westbury, and a MS in organic chemistry from the University of Illinois at Urbana-Champaign. He earned his M.D. from the University of Illinois at Chicago College of Medicine and then completed an FDA Commissioner’s Fellowship Program and stayed on at FDA as a Medical Officer/Medical Consultant.

Dr. William R. Mann is Principal of Lodestar Biopharma Solutions LLC, which assists clients in the development of R&D strategies for regulatory and commercial success, business development, and M&A. Previously, he was President and CEO at Helsinn Therapeutics (US), where he transformed the sixteen employee R&D start-up into a profitable commercial company with a team of over one hundred. At Sapphire Therapeutics, Dr. Mann facilitated an investor exit through M&A while managing the company’s lead clinical development program. He also held leadership positions at Novartis in R&D and business development. Dr. Mann holds a PhD in biochemistry from the University of Aberdeen, Scotland and an MBA from Rutgers University.
“We are excited to have Mario and Bill join us at the Center for Biotechnology. Their extensive and varied industry experiences are wonderful assets to our program. The further expansion of our BEIR Program allows us to continue to advance our agenda, fueling the developing bioscience industry in the region” Diane Fabel, Director of Operations at the Center for Biotechnology said.

“I’m thrilled to become an Executive-in-Residence for the Center for Biotechnology.” stated Dr. Mendoza “I’m greatly looking forward to getting involved with biotech industry innovators collaborating with the organization. I believe the bioscience community in the region is robust and the support and partnership with organizations like the Center for Biotechnology are critical in driving innovation in the biotech space, and in getting innovative patient-centric products to market for the benefit of the patient and healthcare provider communities.”

“The work of the Center for Biotechnology is incredibly important to the bioscience community in the region, and I’m eager to be joining the organization.” Dr. Mann stated. “The innovation potential within the region is immense, and I look forward to the collaborative opportunities that lie ahead.”

Dr. Mann will work to identify a technology or technologies from within LIBH partner institutions that will create the foundation for licensing and company formation. He will have the support of the Center for Biotechnology business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. Ultimately, the goal is to help the company position itself for SBIR/STTR grant opportunities, as well as Angel and VC investment. In his role as Executive-in-Residence, Dr. Mendoza will offer invaluable support to the CFB client company portfolio by providing guidance and expertise in diverse areas including, but not limited to, product development, intellectual property strategy, regulatory affairs, capital formation, medical affairs and reimbursement.

The addition of Drs. Mendoza and Mann marks ten entrepreneurs and two executives-in-residence working with the Center for Biotechnology under their BIER program. Collectively, the Center for Biotechnology BEIRS have launched twelve new companies since the program’s inception in 2013.

View PDF announcement. 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.





The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.





New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.





A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.





New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.





Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy


                    [post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2025-02-26 16:35:20
                    [post_modified_gmt] => 2025-02-26 21:35:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4488
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 2907
                    [post_author] => 1
                    [post_date] => 2018-01-03 15:36:20
                    [post_date_gmt] => 2018-01-03 15:36:20
                    [post_content] => Funding Opportunity Now Available for 2018 Summer Cohort of I-Corps at NIH

Did you know that the NIH and CDC offer entrepreneurship training program for small businesses?

I-Corps at NIH is an experience-based program designed specifically for small biotech businesses. Through this 8-week program, you will learn how to build a strong business model that could help bring your technology to patients.

The Funding Opportunity Announcement (FOA) for 2018 Summer Cohort of I-Corps at NIH is now available: PA-18-517. More information sessions will be available in early 2018 to help you better understand the program. In the meantime, please refer to the following resources to learn more about the program:

    
 	
  • FOA: PA-18-517
    • 
 	
  • Application due date: March 5, 2018, by 5 PM local time
    • 
 	
  • Cohort schedule: June - August 2018
    • 
 	
  • Program Information: I-Corps at NIH Program Page
    • 
 	
  • Recordings of previous info sessions: Webinar Materials page
    • 


If you have any questions about the program, please contact NCI SBIR (ncisbir@mail.nih.gov).
                    [post_title] => Entrepreneurship Training Program from NIH & CDC: I-Corps
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => entrepreneurship-training-program-from-nih-cdc-i-corps
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2018-01-23 14:38:26
                    [post_modified_gmt] => 2018-01-23 14:38:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/?p=2907
                    [menu_order] => 130
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 1428
                    [post_author] => 3
                    [post_date] => 2015-03-02 17:06:37
                    [post_date_gmt] => 2015-03-02 17:06:37
                    [post_content] => The Entrepreneur's Toolkit Workshop is the next installment of how to workshops for entrepreneurs, early phase companies, inventors, and anyone thinking of becoming an entrepreneur. Technology agnostic information on topics such as Seed Funding, Crowd Funding, What is the profile of a fundable company? Protecting my edge in intellectual property? What type of incorporation is right for me? will be presented. View complete agenda here.



This event will be taking place April 21, 2015 at the Center for Wireless and Information Technology at Stony Brook University. View event flyer - Registration for this singular event is at no charge, but space is limited - please reserve your seat here: http://www.cewit.org/newsevents/EntrepreneursToolkitInterestForm.html
                    [post_title] => The Entrepreneur's Toolkit Workshop - April 21, 2015
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => the-entrepreneurs-toolkit-workshop-april-21-2015
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2016-03-02 17:59:51
                    [post_modified_gmt] => 2016-03-02 17:59:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/new/?p=1428
                    [menu_order] => 212
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 3469
                    [post_author] => 3
                    [post_date] => 2020-05-05 08:25:54
                    [post_date_gmt] => 2020-05-05 08:25:54
                    [post_content] => *This list will be updated as opportunities arise. (Updated 7.21.20)

NIH & NIAD Limited Competition Emergency Awards: Shared PPPE Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies

The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”. Rolling deadline - details here: https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_Section_I._Funding



NIH & NIBIB Rapid Acceleration of Diagnostics (RADx) 

Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Learn more: https://www.poctrn.org/radx

Pfizer COVID-19 Competitive Grant Program 

Pfizer has released a Request for Proposals (RFP) to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolving crisis. This competitive grant program from Pfizer Global Medical Grants (GMG) involves a publicly posted RFP that provides details regarding a specific area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. For this RFP, organizations are invited to submit an application addressing the gaps in knowledge and practice of COVID-19 management as outlined here.

Mozilla launches COVID-19 Solutions Fund

Mozilla has created a COVID-19 Solutions Fund as part of the Mozilla Open Source Support Program (MOSS). Through this fund, awards of up to $50,000 each will be provided to open source technology projects which are responding to the COVID-19 pandemic in some way.

As part of the COVID-19 Solutions Fund, applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation)will be accepted. More details here. Application here.

NYS COVID-19 Manufacturing Grants for Masks, Ventilators

The COVID-19 Manufacturing Grants, part of the Jeff Lawrence Innovation Fund, are designed to aid existing New York State small to medium-sized manufacturing companies that can meet prevailing FDA requirements and can quickly accelerate production of personal protective equipment and respiratory care equipment that has been depleted due to the COVID-19 outbreak. Full details here. (Deadline April 17, 2020)

NIBIB announces three COVID-19 Notices of Special Interest

Multiple Notices of Special Interest include administrative supplements and emergency competitive revisions funding for current grantees; SBIR/STTR opportunities; and investigator-initiated research opportunities. Current grantees and new applicants are encouraged to apply immediately. More here.

Fast Grants 

Fast Funding for COVID-19 Science. Scientist at academic institutions currently working on a COVID-19 related project and in need of funding are invited to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. More: fastgrants.org

NIH COVID-Specific Funding Opportunities (Update) 

Multiple Agency NOSI listed here.

National Institute of Allergy and Infectious Diseases: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) RFA-AI-20-028

Administrative Supplements to Existing NIH Grants and Cooperative Agreements: Funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award. More.

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements: Funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner. More.

NSF Request for SBIR/STTR Phase I Proposals Addressing COVID-19

Phase I proposals should focus on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. To apply, you must first develop and submit a Project Pitch at https://seedfund.nsf.gov/apply/. Assuming your pitch is approved, you will be invited by NSF to submit a grant application. More information here.

Department of Defense - Newton Award for Transformative Ideas during the COVID-19 Pandemic

This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. BRO-20-NEWTON (5/5/20 deadline)

COVID-19 Therapeutics Accelerator

Established by The Gates Foundation and Wellcome, this initiative aims to accelerate and evaluate new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. To learn more about the funding process, or how to invest in the accelerator, contact epidemics@wellcome.ac.uk 

Small Business Assistance Programs

Stony Brook University Small Business Development Center is available to assist business owners trough the abundance of resources available for your particular business/industry and to avoid the most common mistake of incomplete or inaccurate Economic Injury Disaster Assistance Loan applications. Visit their website for more information.

Stony Brook University CEAS Student Opportunity: COVID-19 Innovation Teams

Stony Brook University's College of Engineering and Applied Sciences' Vertically Integrated Project Program is focusing special attention on the urgent needs of the COVID-19 pandemic. Learn more.

Innovate2Ventilate: The CoVent-19 Challenge

The CoVent-19 Challenge invites engineers, innovators, designers, and makers to produce rapidly deployable designs for mechanical ventilators. Launching on April 1, 2020, the deadline for the open-entry round of competition is May 1, 2020. Round 2 of the challenge is an invitation-only competition with a deadline of June 1, 2020. More: coventchallenge.com



COVID-19 Funding Opportunities - Summary via Stony Brook University Research 

The funding opportunities listed here are posted on the Pivot database, grants.gov, NIH Guide for Grants and Contracts, and nsf.gov. Detailed information on NIH funding opportunities and other guidance related to COVID-19 can be found here. Investigators should check eligibility and obtain any necessary approvals before applying.

Stony Brook University Faculty Funding Opportunity 

Stony Brook University Office of the Vice President for Research, together with the Institute for Engineering-Driven Medicine, announce this special initiative COVID-19 seed funding opportunity.

The purpose of this program is to seed research that has a direct connection to the current COVID-19 pandemic.Applications are due April 10. Details about eligibility, award amounts and application process can be found here.



Contacting New York State to offer your COVID-19 Resource: 

Businesses with capabilities relevant to needed medical equipment and supplies email to COVID19supplies@esd.ny.gov.

Businesses interested in selling products to the state should contact Simonida Subotic at 646-522-8477 or covid19supplies@exec.ny.gov.

Businesses interested in receiving state funding to manufacture PPE products should contact Eric Gertler at 212-803-3100 or COVID19supplies@esd.ny.gov.

Indie Bio Coronavirus Initiative 

Indie Bio is seeking up to 8 startups to receive a minimum of $250,000 each to pursue the development of diagnostics, therapeutics, vaccines, disinfection, and other solutions addressing the worldwide problem of emerging infectious diseases. More.

BARDA COVID-19 Funding Opportunities

BARDA BAA (no funding limit) 

Novel Coronavirus EZ-BAA (solicitations for funding up to $750K)

Research Foundation of SUNY COVID-19 Funding Opportunities 

**NEW**  SUNY Research Seed Grant Program RFP #20-03-COVID & Submission form.

Aggregate list of opportunities: https://www.rfsuny.org/about-us/covid-19/covid-19-funding/

Biotechnology Innovation Organization (BIO) Coronavirus Resources

Resource page includes Business Resource Center, Service Provider Directory and Coronoavirus Hub where companies can share what they need and how they can help.

CAD $200K ventilator design challenge for COVID-19 patients 

the Challenge is lead by Code Life.ca and the Montreal General Hospital foundations. The designs are due end of March 2020. The details and rules are posted there, and participants can sign up to begin: https://www.agorize.com/en/challenges/code-life-challenge/

OTHER CHALLENGES

Business Incubator Association of New York State - Innovate to Ventilate 

Hauppauge Industrial Association of Long Island (HIA-LI) Pivot to PPE

RESOURCES

COVID-19 Open Research Dataset (CORD-19)
Ginkgo commits $25M of free access to platform for partner COVID-19 projects

 
                    [post_title] => COVID-19 Funding and Resource Opportunities
                    [post_excerpt] => An aggregate list of COVID-19 related funding opportunities and technology and business related resources. This list will be updated as opportunities arise. 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => covid-19-resources
                    [to_ping] => 
                    [pinged] => 
https://indiebio.co/indiebio-covid-response/
                    [post_modified] => 2024-12-03 15:00:20
                    [post_modified_gmt] => 2024-12-03 20:00:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3469
                    [menu_order] => 71
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [post_count] => 4
    [current_post] => -1
    [before_loop] => 1
    [in_the_loop] => 
    [post] => WP_Post Object
        (
            [ID] => 4488
            [post_author] => 4
            [post_date] => 2024-10-24 10:45:00
            [post_date_gmt] => 2024-10-24 14:45:00
            [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.





The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.





New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.





A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.





New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.





Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy


            [post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2025-02-26 16:35:20
            [post_modified_gmt] => 2025-02-26 21:35:20
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://centerforbiotechnology.org/?p=4488
            [menu_order] => 0
            [post_type] => post
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [comment_count] => 0
    [current_comment] => -1
    [found_posts] => 269
    [max_num_pages] => 90
    [max_num_comment_pages] => 0
    [is_single] => 
    [is_preview] => 
    [is_page] => 
    [is_archive] => 
    [is_date] => 
    [is_year] => 
    [is_month] => 
    [is_day] => 
    [is_time] => 
    [is_author] => 
    [is_category] => 
    [is_tag] => 
    [is_tax] => 
    [is_search] => 
    [is_feed] => 
    [is_comment_feed] => 
    [is_trackback] => 
    [is_home] => 1
    [is_privacy_policy] => 
    [is_404] => 
    [is_embed] => 
    [is_paged] => 
    [is_admin] => 
    [is_attachment] => 
    [is_singular] => 
    [is_robots] => 
    [is_favicon] => 
    [is_posts_page] => 
    [is_post_type_archive] => 
    [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
    [query_vars_changed:WP_Query:private] => 
    [thumbnails_cached] => 
    [allow_query_attachment_by_filename:protected] => 
    [stopwords:WP_Query:private] => 
    [compat_fields:WP_Query:private] => Array
        (
            [0] => query_vars_hash
            [1] => query_vars_changed
        )

    [compat_methods:WP_Query:private] => Array
        (
            [0] => init_query_flags
            [1] => parse_tax_query
        )

)

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

October 24, 2024

More Information

Entrepreneurship Training Program from NIH & CDC: I-Corps

January 3, 2018

More Information

The Entrepreneur’s Toolkit Workshop – April 21, 2015

March 2, 2015

More Information

COVID-19 Funding and Resource Opportunities

May 5, 2020

More Information